Molecular Docking and Dynamic Simulation Studies of Bioactive Compounds from Traditional Medicinal Compounds Against Exfoliative Toxin B from Staphylococcus aureus

ABSTRACT

Background: Staphylococcal scalded skin syndrome (SSSS) is a dermatological condition caused by Staphylococcus aureus, characterized by exfoliative toxin B, and its increasing resistance to conventional antibiotics necessitates the search for new therapeutic options. Aim: The study aimed to investigate the potential of traditional medicinal compounds (TMCs) as potential pharmaceuticals against SSSS using molecular-level research. Introduction: Staphylococcus aureus, commonly known as S. aureus, is the main cause of SSSS. These infections are a major concern for public health because they are becoming resistant to antibiotics. There is an urgent need for new medications to effectively fight against this infection. The main objective of this study was to assess the interaction between TMC compounds and S. aureus exfoliative toxins ETA and ETB utilizing computational approaches. Materials and Methods: The investigation selected TMC compounds based on their potential to combat S. aureus infections. To predict binding affinities with the ETB toxin, molecular docking simulations were performed using AutoDock and AutoDock Vina. In order to evaluate the stability and interaction dynamics with the toxins, the most promising compound was subjected to a 100 ns molecular dynamics simulation. Stability was evaluated through various methods. Results: Liquiritin showed the highest binding affinity, with a docking score of −7.6 kcal/mol. MD simulation confirmed the complex’s stability, and the binding free energy of −17.76 kcal/mol indicated potent inhibitory activity against S. aureus ETB. Conclusion: Liquiritin, a TMC, effectively inhibits S. aureus toxins ETB, with promising potential for treating SSSS and antibiotic-resistant infections, requiring further research.

KEYWORDS

• Staphylococcal scalded skin syndrome
• exfoliative toxin B
• traditional medicine
• molecular docking
• MD simulation
• MM-GBSA

Showing references and in-text citations exactly as published.

Cite this article

• DOI10.1177/1266072Copy

RELATED ARTICLES

Matched on section and article type within this issue of J Pharmacol. Pharmacother..

• Article · VOLUME 15, ISSUE 3Comparing the Effect of Intravenous Tramadol and Intravenous Nalbuphine in Addition to Midazolam for the Control of Shivering after Spinal AnesthesiaApoorva Madem, Sravanthi Parusha, Dinakar Mallem, Indira Pacharla, Vijay Kotra, Wen Han Chooi, Rebecca Shin Yee Wong, Long Chiau Ming, Ali Saleh Alkhoshaiban, Khang Wen Goh · pp. 264–276Research ArticleSame type: Article
• Article · VOLUME 15, ISSUE 3Effect of Coping Strategies on Pain Intensity in Patients with Rheumatoid ArthritisK Rohith Chandra, B Jeevan Kumar, D Mubeen Taj, Pavani M, Kondaveeti Devaki, Nunavath Raja Shekhar, Sirisha Kommireddy, Ajay Kumar Chittipolu, Goutham Yerrakula · pp. 277–283Research ArticleSame type: Article
• Article · VOLUME 15, ISSUE 3Exploration of Active Ingredients, Targets, and Potential Mechanisms of Er-Miao-San in the Treatment of Colorectal Cancer Based on Network Pharmacology and Molecular Docking TechnologyLin Zhou, Jinyan Chu, Chenyue Yuan, Yong Zhao, Yuting Yan, Lin Jing, Jianlin Ren · pp. 284–297Research ArticleSame type: Article
• Article · VOLUME 15, ISSUE 3Pharmacological Study of Guben Yifei-Tang on a Rat Model of PneumoconiosisZhou Yang, Shi Wenting, Haiming Lei, Weihong Shi · pp. 298–305Research ArticleSame type: Article